Arlinda Lee
Stock Analyst at Canaccord Genuity
(1.73)
# 2,084
Out of 4,479 analysts
27
Total ratings
50%
Success rate
18.6%
Average return
Main Sectors:
Top Industries:
15 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $18 → $21 | $7.91 | +165.49% | 3 | Sep 7, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $20 → $10 | $0.54 | +1,737.22% | 1 | Apr 5, 2022 | |
| BNTX BioNTech SE | Maintains: Buy | $450 → $300 | $78.76 | +280.90% | 5 | Apr 5, 2022 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $25 → $6 | $1.17 | +412.82% | 4 | Mar 16, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $45 → $36 | $42.34 | -14.97% | 1 | Mar 7, 2022 | |
| CELC Celcuity | Initiates: Buy | n/a | $16.19 | - | 1 | Oct 8, 2021 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | n/a | $53.12 | - | 1 | Aug 16, 2021 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | n/a | $19.81 | - | 1 | Jul 13, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | n/a | $40.96 | - | 3 | Jul 2, 2020 | |
| BDTX Black Diamond Therapeutics | Initiates: Buy | n/a | $4.21 | - | 1 | Feb 24, 2020 | |
| CARA Cara Therapeutics | Maintains: Buy | n/a | $0.28 | - | 2 | Aug 15, 2018 | |
| AKTX Akari Therapeutics, | Maintains: Buy | n/a | $3.10 | - | 1 | Mar 29, 2018 | |
| KPTI Karyopharm Therapeutics | Maintains: Buy | n/a | $0.80 | - | 1 | Mar 12, 2018 | |
| HALO Halozyme Therapeutics | Maintains: Buy | n/a | $51.30 | - | 1 | Nov 8, 2017 | |
| BPMC Blueprint Medicines | Maintains: Buy | n/a | $110.36 | - | 1 | Sep 20, 2017 |
Delcath Systems
Sep 7, 2023
Maintains: Buy
Price Target: $18 → $21
Current: $7.91
Upside: +165.49%
X4 Pharmaceuticals
Apr 5, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $0.54
Upside: +1,737.22%
BioNTech SE
Apr 5, 2022
Maintains: Buy
Price Target: $450 → $300
Current: $78.76
Upside: +280.90%
Nektar Therapeutics
Mar 16, 2022
Maintains: Buy
Price Target: $25 → $6
Current: $1.17
Upside: +412.82%
Rhythm Pharmaceuticals
Mar 7, 2022
Maintains: Buy
Price Target: $45 → $36
Current: $42.34
Upside: -14.97%
Celcuity
Oct 8, 2021
Initiates: Buy
Price Target: n/a
Current: $16.19
Upside: -
CRISPR Therapeutics AG
Aug 16, 2021
Maintains: Buy
Price Target: n/a
Current: $53.12
Upside: -
Bicycle Therapeutics
Jul 13, 2021
Maintains: Buy
Price Target: n/a
Current: $19.81
Upside: -
Ultragenyx Pharmaceutical
Jul 2, 2020
Maintains: Buy
Price Target: n/a
Current: $40.96
Upside: -
Black Diamond Therapeutics
Feb 24, 2020
Initiates: Buy
Price Target: n/a
Current: $4.21
Upside: -
Cara Therapeutics
Aug 15, 2018
Maintains: Buy
Price Target: n/a
Current: $0.28
Upside: -
Akari Therapeutics,
Mar 29, 2018
Maintains: Buy
Price Target: n/a
Current: $3.10
Upside: -
Karyopharm Therapeutics
Mar 12, 2018
Maintains: Buy
Price Target: n/a
Current: $0.80
Upside: -
Halozyme Therapeutics
Nov 8, 2017
Maintains: Buy
Price Target: n/a
Current: $51.30
Upside: -
Blueprint Medicines
Sep 20, 2017
Maintains: Buy
Price Target: n/a
Current: $110.36
Upside: -